Cerus Reports Third Quarter 2016 Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) today announced financial results for the third quarter ended September 30, 2016.
Recent developments include:
• The U.S. Food and Drug Adminisration’s (FDA) revised recommendations for protecting blood components from Zika virus was expanded to recommend use of pathogen reduction technology and/or an investigational blood screening test to all U.S. blood centers.
Recent developments include:
• The U.S. Food and Drug Adminisration’s (FDA) revised recommendations for protecting blood components from Zika virus was expanded to recommend use of pathogen reduction technology and/or an investigational blood screening test to all U.S. blood centers.